Interferons 发表于 2025-3-23 11:25:17

Submitted on: 16 November 2009.
Revised on: 16 December 2009.
Accepted on: 01 January 2010.
Ophthalmology and Therapy---SPRINGER INT PUBL AG

Control-Group 发表于 2025-3-23 17:04:04

Submitted on: 07 November 2001.
Revised on: 01 December 2001.
Accepted on: 22 December 2001.
Ophthalmology and Therapy

Interdict 发表于 2025-3-23 21:06:40

Submitted on: 03 September 2003.
Revised on: 06 October 2003.
Accepted on: 12 October 2003.
Ophthalmology and Therapy---SPRINGER INT PUBL AG

coltish 发表于 2025-3-24 01:32:05

Submitted on: 10 October 2007.
Revised on: 18 November 2007.
Accepted on: 09 December 2007.
Ophthalmology and Therapy---SPRINGER INT PUBL AG

atrophy 发表于 2025-3-24 04:31:03

http://reply.papertrans.cn/3/237/23697/23697-15.png

抱负 发表于 2025-3-24 08:22:46

http://reply.papertrans.cn/3/237/23697/23697-16.png

征税 发表于 2025-3-24 10:46:36

http://reply.papertrans.cn/3/237/23697/23697-17.png

flaggy 发表于 2025-3-24 17:42:51

Submitted on: 06 December 2020.
Revised on: 22 December 2020.
Accepted on: 19 January 2021.
Ophthalmology and Therapy

falsehood 发表于 2025-3-24 19:28:31

Submitted on: 15 March 2015.
Revised on: 21 April 2015.
Accepted on: 26 April 2015.
Ophthalmology and Therapy---SPRINGER INT PUBL AG

核心 发表于 2025-3-24 23:23:11

Submitted on: 03 August 2016.
Revised on: 16 August 2016.
Accepted on: 31 August 2016.
Ophthalmology and Therapy
页: 1 [2] 3 4
查看完整版本: SCIE期刊Ophthalmology and Therapy 2024/2025影响因子:2.666 (OPHTHALMOL THER) (2193-8245). (OPHTHALMOLOGY)(眼科学)Science Citation